From:  Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia

 The spectrum of treatment-related adverse events in patients treated with lorlatinib.

AEsOverall, n (%)Grade 1–2, n (%)Grade 3–4, n (%)
Hyperlipidemia46 (56.1)43 (52.4)3 (3.7)
Peripheral edema17 (20.7)17 (20.7)-
Neurocognitive AEs7 (8.5)5 (6.1)2 (2.4)
    Cognitive impairment3 (3.7)3 (3.7)-
    Mood events3 (3.7)2 (2.4)1 (1.2)
    Psychotic events1 (1.2)0 (0.0)1 (1.2)
Weight gain6 (7.3)6 (7.3)-
Peripheral neuropathy3 (3.7)3 (3.7)-
Creatinine increased2 (2.4)2 (2.4)-
AEs leading to dose reduction14 (17.1)--
AEs leading to dose discontinuation0 (0.0)--

AEs: adverse events; -: not applicable.